Blarney’s facility Opening
Merck KGaA opens climate-neutral €150 million filter manufacturing facility in Ireland
On September 18, 2025Merck, a leading science and technology company, has opened today its €150 million filter manufacturing facility in Blarney Business Park, Cork, Ireland. The site is Merck’s first manufacturing facility designed for full climate-neutral operations, marking a key milestone in the
company’s ambition to achieve climate neutrality by 2040.
The 3,000-square-meter cleanroom facility supports global demand for critical filtration products used in the manufacturing of vaccines and life-saving therapies, including monoclonal antibodies, and emerging modalities like cell and gene therapies. By localizing these capacities in Europe, Merck hopes to reduce cross-border dependencies for the company’s customers.
The facility is expected to begin production in the fourth quarter of 2025 and will manufacture filtration devices used in aseptic processing, tangential-flow filtration and virus filtration. These filtration technologies are key components of most bioprocessing templates and are vital to controlling bioburden, streamlining purification and removing viral contaminants. They assure vaccines and therapeutics meet expected purity standards and are safe for administration to patients. The new site will run on 100% renewable electricity and an innovative heat recovery system, which is estimated to avoid up to 61 metric tons of CO2 equivalents annually. It will also reuse up to 95% of high-purity reverse osmosis water from its
filtration manufacturing process.
The Blarney Business Park facility is part of Merck’s largest Life Science investment to date. Together with the nearby Carrigtwohill site, the company has committed €440 million to expand membrane and filtration manufacturing in Ireland. These investments are part of Merck’s €2 billion Life Science global expansion program, announced in 2020, to meet growing demand for life-saving therapies across
Europe, China, and the United States.
Anne-Lise Berthier
Merck KGaA opens climate-neutral €150 million filter manufacturing facility in Ireland
Blarney’s facility Opening
Merck KGaA opens climate-neutral €150 million filter manufacturing facility in Ireland
On September 18, 2025Merck, a leading science and technology company, has opened today its €150 million filter manufacturing facility in Blarney Business Park, Cork, Ireland. The site is Merck’s first manufacturing facility designed for full climate-neutral operations, marking a key milestone in the
company’s ambition to achieve climate neutrality by 2040.
The 3,000-square-meter cleanroom facility supports global demand for critical filtration products used in the manufacturing of vaccines and life-saving therapies, including monoclonal antibodies, and emerging modalities like cell and gene therapies. By localizing these capacities in Europe, Merck hopes to reduce cross-border dependencies for the company’s customers.
The facility is expected to begin production in the fourth quarter of 2025 and will manufacture filtration devices used in aseptic processing, tangential-flow filtration and virus filtration. These filtration technologies are key components of most bioprocessing templates and are vital to controlling bioburden, streamlining purification and removing viral contaminants. They assure vaccines and therapeutics meet expected purity standards and are safe for administration to patients. The new site will run on 100% renewable electricity and an innovative heat recovery system, which is estimated to avoid up to 61 metric tons of CO2 equivalents annually. It will also reuse up to 95% of high-purity reverse osmosis water from its
filtration manufacturing process.
The Blarney Business Park facility is part of Merck’s largest Life Science investment to date. Together with the nearby Carrigtwohill site, the company has committed €440 million to expand membrane and filtration manufacturing in Ireland. These investments are part of Merck’s €2 billion Life Science global expansion program, announced in 2020, to meet growing demand for life-saving therapies across
Europe, China, and the United States.
Anne-Lise Berthier
COMMENTS ARE OFF THIS POST